Skip to content

Study on improving cognitive function of stable schizophrenic patients by digital cognitive function training

Study on improving cognitive function of stable schizophrenic patients by digital cognitive function training

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200055930
Enrollment
Unknown
Registered
2022-01-26
Start date
2021-12-12
Completion date
Unknown
Last updated
2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia

Interventions

Intervention group:Digital cognitive function training
Control group:Regular treatment

Sponsors

Peking Universality Sixth Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosis of schizophrenia according to DSM-5 criteria; 2. Aged 18-50 years; 3. Course of disease <=5 years; 4. Can understand the content of informed consent and research process, and sign informed consent; 5. There was no significant drug adjustment in 2 months, and no plan of drug adjustment in the next 6 months; 6. Evidence of no symptom fluctuation 2 months before enrollment: no hospitalization for schizophrenia, no increase in treatment due to disease aggravation; 7. PANSS score: P1 (delusion), P2 (conceptual disorder), P3 (hallucination), N1 (emotional retardation), N4 (social withdrawal), N6 (lack of spontaneity and fluency in conversation), G5 (affectation and posturing), G9 (abnormal thinking content) <= 3 points.

Exclusion criteria

Exclusion criteria: 1. Pre-existing or current diseases that may affect cognitive function, including but not limited to mental retardation, dementia, alcohol or other substance dependence, head trauma with loss of consciousness for more than 1 hour, etc.; 2. Currently taking methylphenidate, anti-dementia drugs, amphetamine, lithium salts, monoamine oxidase inhibitors, tricyclic antidepressants; 3. Currently taking first-generation antipsychotic drugs or clozapine; 4. There is a risk of suicide (suicidal behavior in the past 1 year, suicidal idea or attempt in the past 3 months); 5. She had received MECT or rTMS in the last 6 months; 6. There are contraindications to MRI, such as pacemaker and nerve stimulator, metal in the body, etc.

Design outcomes

Primary

MeasureTime frame
MRI;

Countries

China

Contacts

Public ContactShi Chuan

Peking Universality Sixth Hospital

shichuan@bjmu.edu.cn+86 18273126670

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026